Apitope Led Consortium Receives Up To €6M FP7 Funding To Develop Novel Therapeutic Vaccine For Graves' Disease
1/8/2014 9:40:38 AM
BRISTOL, England & HASSELT, Belgium--(BUSINESS WIRE)--Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces that the consortium, led by Apitope, which includes GSK Vaccines, Quintiles and KWS Biotest Limited, has been awarded prestigious Framework Programme 7 (FP7) Health Innovation funding by the European Commission to develop its Graves’ disease therapeutic vaccine, including a Phase I first-in-man study in Graves’ disease patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by